Real-world use of chemotherapy forKaposi’s sarcoma in a large community-based HIV primary care system in Kenya

Abstract

Background:Kaposi’s sarcoma (KS) is one of the most common HIV-associated malignancies in sub-Saharan Africa.Worldwide, the availability of antiretroviral therapy (ART) has improved KS survival. In resource-rich settings, survival has also benefited from chemotherapy, which is widely available. Little is known, however, about the epidemiology of chemotherapy use for HIV-associated KS in resource-limited regions such as sub-Saharan Africa.Methods:We identified all patients newly diagnosed with HIV-related KS from 2009 to 2012 in the 26-clinicAMPATH network, a large community-based care network in Kenya. We ascertained disease severity at diagnosis,frequency of initiation of chemotherapy, and distribution of chemotherapeutic regimens used. Indications for chemotherapy included AIDS Clinical Trial Group T1 stage and/or“severe”disease defined by WHO KS treatment guidelines.Results:Of 674 patients diagnosed with KS, charts were available for 588; 61% were men, median age was 35 years,and median CD4 at KS diagnosis was 185 cells/μl. At time of diagnosis, 58% had at least one chemotherapy indication, and 22% had more than one indication. For patients with a chemotherapy indication, cumulative incidence of chemotherapy initiation (with death as a competing event) was 37% by 1 month and 56% by 1 year.Median time from diagnosis to chemotherapy initiation was 25 days (IQR 1–50 days). In multivariable regression,patients with> 3 chemotherapy indications at time of diagnosis had a 2.30 (95% CI 1.46–3.60) increased risk ofrapid chemotherapy initiation (within 30 days of diagnosis) compared to those with only one chemotherapy indication (p< 0.001). Initial regimens were bleomycin-vincristine (78%), adriamycin-bleomycin-vincristine (11%),etoposide (7%), and gemcitabine (4%).Conclusions:A substantial fraction of patients with KS in East Africa are diagnosed at advanced disease stage. For patients with chemotherapy indications, nearly half did not receive chemotherapy by one year. Liposomalanthracyclines, often used in resource-rich settings, were not first line. These findings emphasize challenges in Eas tAfrica cancer care, and highlight the need for further advocacy for improved access to higher quality chemotherapy in this setting.